# IMGT Co.

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/imgt-co

- Industry: Biotechnology
- Headquarters: Seongnam, South Korea
- Website: www.imgt.co.kr
- Total disclosed funding: $23M
- Latest round: Series C (Dec 17, 2021)
- Investors on record: 10

## About

IMGT Co., Ltd. is a South Korean company specializing in the development of advanced technology solutions aimed at enhancing operational efficiency and data management for various industries.Founded in 2010 and headquartered in Seongnam, South Korea, IMGT Co., Ltd. focuses on innovative technology solutions. The company has undergone strategic pivots to enhance its offerings and has successfully closed five deals to date. The founder, Marie-Paule Lefranc, has a history of entrepreneurial ventures, further strengthening the company's leadership. In December 2021, IMGT raised KRW 15.2 billion in Series C funding from multiple investors including ANDA Asset Management and others, marking a significant milestone in its funding journey.IMGT Co., Ltd. delivers innovative technology solutions tailored to various industries, primarily through its advanced software platforms. These platforms improve operational efficiency and data management for medium to large enterprises across sectors such as healthcare, finance, and manufacturing. The company focuses on providing tools that streamline processes and enhance analytics, with a strong market presence in North America, Europe, and parts of Asia, known for their reliability and innovative features.The company's revenue model includes subscription services and direct sales, where clients typically subscribe annually to access software updates and support. Customized solutions are offered based on specific client needs, ensuring a tailored approach to their operational challenges. IMGT's flagship products, recognized for their functionality and user-friendly design, significantly contribute to revenue generation, supported by strategic partnerships for broader market reach.Following the Series C funding raised in December 2021, IMGT Co., Ltd. plans to utilize the KRW 15.2 billion to advance the development of their ultrasound-sensitive drug delivery systems and therapeutic ultrasound devices, focusing on conducting clinical trials. The company aims to introduce new products that enhance healthcare solutions and is exploring expansion into additional markets, particularly in Europe and Asia, by 2023.

## Funding rounds

- Series C, Dec 17, 2021, $13M — Korea Investment Partners, KDB Capital, L&S Venture Capital, K2 Investment Partners, ANDA Asset Management, DB Securities, Rico Asset Management, CK Goldilocks Asset Management, Huons Global
- Series B, Jan 24, 2019, $8.7M — Korea Investment Partners, KDB Capital, K2 Investment Partners, IBK Capital
- Series A, Dec 1, 2016, $1.6M — K2 Investment Partners

## Investors

- K2 Investment Partners (https://capitalatlas.ai/funds/k2-investment-partners) — Series A, Series B, Series C
- Korea Investment Partners (https://capitalatlas.ai/funds/korea-investment-partners) — Series B, Series C
- KDB Capital (https://capitalatlas.ai/funds/kdb-capital) — Series B, Series C
- IBK Capital (https://capitalatlas.ai/funds/ibk-capital) — Series B
- L&S Venture Capital (https://capitalatlas.ai/funds/l-s-venture-capital) — Series C
- ANDA Asset Management (https://capitalatlas.ai/funds/anda-asset-management) — Series C
- DB Securities (https://capitalatlas.ai/funds/db-securities) — Series C
- Rico Asset Management — Series C
- CK Goldilocks Asset Management — Series C
- Huons Global — Series C